Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

Prelude Therapeutics Incorporated (PRLD)

Compare
0.7703
+0.0023
+(0.30%)
At close: April 1 at 4:00:00 PM EDT
0.8200
+0.05
+(6.45%)
After hours: April 1 at 7:54:26 PM EDT

Research Analysis

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 4M
Earnings -28.73M

Q1'24

Q2'24

Q3'24

Q4'24

-30M
-20M
-10M
0
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

1.00
3.33 Average
0.7703 Current
5.00 High

Earnings Estimate

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
No. of Analysts 1122
Avg. Estimate -0.46-0.47-1.46-1.06
Low Estimate -0.46-0.47-1.88-1.68
High Estimate -0.46-0.47-1.04-0.43
Year Ago EPS -0.42-0.46-1.68-1.46

Revenue Estimate

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
No. of Analysts 2221
Avg. Estimate --------
Low Estimate --------
High Estimate --------
Year Ago Sales ----7M--
Sales Growth (year/est) 0.00%0.00%-100.00%0.00%

Earnings History

Currency in USD 3/31/2024 6/30/2024 9/30/2024 12/31/2024
EPS Est. -0.48-0.43-0.46-0.47
EPS Actual -0.42-0.46-0.43-0.37
Difference 0.06-0.030.030.1
Surprise % 13.22%-7.60%7.48%20.81%

EPS Trend

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
Current Estimate -0.46-0.47-1.46-1.06
7 Days Ago -0.44-0.44-1.5-1.69
30 Days Ago -0.44-0.44-1.5-1.69
60 Days Ago -0.44-0.44-1.5-1.69
90 Days Ago -0.44-0.44-1.5-1.69

EPS Revisions

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days 1111
Down Last 30 Days 1111

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
PRLD -9.52%-2.17%13.15%27.62%
S&P 500 6.69%6.80%9.98%14.34%

Upgrades & Downgrades

Reiterates Citizens Capital Markets: Market Outperform to Market Outperform 3/12/2025
Reiterates JMP Securities: Market Outperform to Market Outperform 12/11/2024
Reiterates HC Wainwright & Co.: Buy to Buy 11/8/2024
Reiterates HC Wainwright & Co.: Buy to Buy 10/28/2024
Upgrade HC Wainwright & Co.: Neutral to Buy 9/19/2024
Reiterates JMP Securities: Market Outperform to Market Outperform 9/16/2024

Related Tickers